Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 10/20 | 0.75 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3202663 | 0.91 | CRHR1 (0.74) | CRHR1PTGS2ACACB | |
| SCHEMBL2055981 | 0.86 | CRHR1 (1.00) | CRHR1ACACB | |
| SCHEMBL3208206 | 0.84 | CRHR1 (0.81) | CRHR1ACACB | |
| SCHEMBL2056007 | 0.84 | CRHR1 (0.92) | CRHR1ACACB | |
| SCHEMBL2055983 | 0.84 | CRHR1 (0.80) | CRHR1ACACB | |
| SCHEMBL3199637 | 0.83 | CRHR1 (0.79) | CRHR1ACACB | |
| SCHEMBL3199284 | 0.83 | CRHR1 (0.84) | CRHR1ACACB | |
| SCHEMBL3199610 | 0.83 | CRHR1 (0.84) | CRHR1ACACB | |
| SCHEMBL3207503 | 0.82 | CRHR1 (0.78) | CRHR1ACACB | |
| SCHEMBL3209932 | 0.82 | CRHR1 (1.00) | CRHR1ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056515-A1 | BENZIMIDAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | claimed |
| US-20100056515-A1 | BENZIMIDAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056515-A1 | BENZIMIDAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056515-A1 | BENZIMIDAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2088861-A2 | BENZIMIDAZOLE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008051533-A2 | BENZIMIDAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008051533-A2 | BENZIMIDAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056515-A1 | BENZIMIDAZOLE COMPOUNDS | HRH4, SSTR5, CNR1 | CRHR1 4/4885NR1H2 162/4885NR1H3 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.